Navigation Links
HIV/AIDS linked to extensively drug resistant TB

A highly drug-resistant form of tuberculosis (TB) has been linked to HIV/AIDS in a study conducted in rural South Africa by researchers at Yale School of Medicine.

Published in the October 26 issue of The Lancet, the study is the result of a five-year collaboration between a Yale and South African team of researchers who aim to integrate HIV and TB care and treatment.

TB is the most common cause of death and illness in those with HIV infection in sub-Saharan Africa. HIV greatly increases the risk of active TB disease and about 80 percent of patients with active TB in the province of KwaZulu Natal, South Africa, are co-infected with HIV. Death rates of up to 40 percent per year have been reported in patients with both HIV and TB.

Led by senior author Gerald Friedland, M.D., director of the AIDS Program at Yale and Professor in the Departments of Medicine and Epidemiology and Public Health, the study measured the prevalence of multi-drug resistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis in a hospital in KwaZulu Natal. Between January 2005 and March 2006, sputum samples from 1,539 patients were screened. MDR TB was found in 221 patients and of those, 53 had XDR TB. Those patients with XDR who were tested for HIV were found to be co-infected. All but one of the 53 patients with both XDR TB and HIV died, with an average survival of 16 days.

"This is an issue of grave worldwide importance," said Friedland. "MDR and XDR carry the danger of blunting or reversing the success of TB programs and the roll-out of anti-retroviral therapies for HIV where they are desperately needed in resource limited settings. Urgent intervention is necessary, especially now that we know that MDR tuberculosis is far more prevalent than previously thought and that XDR tuberculosis has been transmitted to HIV co-infected patients and associated with high mortality."

Future studies will involve defining the extent and conseq
'"/>

Source:Yale University


Page: 1 2

Related biology news :

1. New therapy for HIV/AIDS eliminates needles and excessive toxicity
2. South Africa still debating how to tackle HIV/AIDS when 5 million are infected
3. AIDS expert says global strategy needed to combat feminization of HIV/AIDS
4. Progress on HIV/AIDS significant but insufficient
5. HIV/AIDS rates in Tijuana, Mexico increasing at alarming rate
6. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
7. Study defines effective microbicide design for HIV/AIDS prevention
8. Rhesus monkeys in Nepal may provide new alternative for HIV/AIDS research
9. Cornell researcher helping develop quick, cheap HIV/AIDS test
10. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
11. Low level of extinction during ice age linked to adaptability
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: HIV AIDS linked extensively drug resistant

(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... best friend might just be treated like any other animal ... Blouin, assistant professor of the Department of Sociology and Anthropology ... of animals as children tend to have a city background. ... not uncommon in rural areas," Blouin said, "which makes sense ...
... Carolina State University have developed a method for predicting ... including the human body. Their work could have implications ... handling of nanomaterials, as well as applications for drug ... Wellcome Distinguished Professor of Pharmacology and director of ...
... BIO-key International, Inc. (OTC Bulletin Board: http://photos.prnewswire.com/prnh/20050509/BIOKEYLOGO ) ... What: , BIO-key International, Inc. Second Quarter 2010 ... Thursday, July 29, 2010 - 10:00 a.m. Eastern Time , ... via phone by dialing 800-860-2442 and asking for the BIO-key call at ...
Cached Biology News:Dogs' family status depends on family's locale 2Probing the nanoparticle: Predicting how nanoparticles will react in the human body 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 3
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  NeuroLifeSciences announced ... mazindol in children with attention deficit/hyperactivity disorder published in ... . The paper, titled "Pilot Phase ... disorder" ( Konofal et al, Drug Des ... ) shows that mazindol might be an effective, ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Hutchings has assumed leadership of Egon Zehnder International,s North ... the practice, will continue at the firm in an ... In his new role, Mr. Hutchings will be ... and providing the full array of functional leadership capabilities ...
... 2010 Clarient, Inc. ("Clarient") (Nasdaq: CLRT ) ... "Offer") by Crane Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned ... GE ) to acquire all of the outstanding shares of ... of the Offer from midnight, New York City time, at ...
... Dec. 3, 2010 Gentiva Health Services, Inc. ... home health and hospice services, announced today that it has ... 2010, at 10:00 a.m. ET to provide an update on ... the morning of December 16 before pre-market trading. ...
Cached Biology Technology:Egon Zehnder International Names Todd Hutchings to Lead Life Sciences Practice Group 2Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation 2Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation 3Clarient Tender Offer Extended; Clarient Makes Additional Disclosures to Settle Litigation 4Gentiva® Health Services Schedules 2011 Outlook Conference Call and Webcast for Thursday, December 16, 2010 2Gentiva® Health Services Schedules 2011 Outlook Conference Call and Webcast for Thursday, December 16, 2010 3
... to ATP-binding proteins. To create this ... was linked through the Gamma-thiol of ... use for binding studies the BODIPY ... new substrate for Fhit a member ...
... Using information-rich MSn data, the ... of multiple levels of fragmentation, isotope ... techniques to accurately determine the correct ... Traditional approaches for deducing empirical formulae ...
... custom peptide synthesis with a wide variety of ... your research needs. Purity: IG(>50%), ... 2mg-1g Sequence Length: Up to ... N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, KLH/BSA conjugation, ...
... 50 mg/L streptomycin sulfate, 100 mg/L kanamycin ... magnesium chloride. The use of a balanced ... generally attributed to early workers in the ... solution of inorganic salts designed to maintain ...
Biology Products: